Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study

Is Hyponatraemia a Risk Factor for Mortality in Schizophrenic and Bipolar Patients? Protocol for a Bayesian Causal Inference Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04409626

Enrollment

31740

Registered

2020-06-01

Start date

2011-01-01

Completion date

2020-08-31

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyponatremia, SIADH

Keywords

Causality, Bayesian analysis, Antipsychotics, Psychotropics, Polypharmacy

Brief summary

This study seeks to investigate if hyponatraemia be a direct contributor to death in schizophrenic and bipolar patients, and gauge the potential role of somatic comorbidity and psychotropic polypharmacy, with emphasis on antipsychotics and antidepressants.

Interventions

OTHERPlasma sodium level (continuous variables)

Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Source population: * Danish residents * At least one International Classification of Diseases version 10 (ICD-10) F2 or F31 diagnosis from a hospital in Region Zealand and the Capital Region (Denmark) No

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Mortality	1 January 2011 through 1 July 2016	All-cause mortality

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026